CCM
RIGL icon

Cadence Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Cadence Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-64,135
Closed -$1M – 445
2020
Q1 		$1M Buy
+64,135
New +$1.37M 0.17% 189

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cadence Capital Management's RIGL Position: Q2 2020 in Review

Cadence Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2020, closing a stake of 64,135 shares — an estimated $1M sold.

Cadence Capital Management first reported a position in RIGL in Q1 2020 and held it in 1 quarter. The position peaked at $1M in Q1 2020. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2020.

  • Cadence Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Cadence Capital Management sold 64,135 Rigel Pharmaceuticals shares in Q2 2020, an estimated $1M.
  • Cadence Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Cadence Capital Management's Rigel Pharmaceuticals position peaked at $1M in Q1 2020.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2020.

Based on Cadence Capital Management's 13F filing for Q2 2020, filed 3 Aug 2020.